#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours par raspansa:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Hamel Lawrence G  (Last) (First) (Middle)					<u>A(</u>	2. Issuer Name and Ticker or Trading Symbol ACELRX PHARMACEUTICALS INC ACRX								5. Relationship of Report (Check all applicable)  Director  X  Officer (give title below)			Ü	10% (	Owner (specify
C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 02/11/2020									C1	nief Devel	lopm	ent Office	r	
(Street) REDWO CITY (City)	C.F		)4063 Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ind Line) X					son
(City)	(51			n-Deriv	rative		curiti		nuired	Die	nosed o	f or F	Renefic	vilei	Own				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da			ction	tion 2A. Deemed Execution Date,			3. Transa Code (	Transaction Disposed Of (D) (Instr. 3, 4 a Code (Instr. 5)			r	5. Amount of		Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)	or Pric	е	Transac	saction(s) r. 3 and 4)			(Instr. 4)
Common	Stock			02/11/	2020	D20 F 5,613 <sup>(1)</sup> D \$1.71 127,769 <sup>(2)</sup> D						D							
Common Stock															29	),795		I	By the Hamel Revocable Living Trust
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	e Conversion or Exercise Price of Derivative Security  Date (Month/Day/Year)  Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)	(Instr.		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Exercisable Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amount or Numbe of Title Shares		t r		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

### **Explanation of Responses:**

- 1. Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- 2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

#### Remarks:

/s/ Martha Adler, Attorney-In-02/13/2020 **Fact** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.